Rapamycin and Telomere State
Rapamycin extended lifespan in wild-type mice but decreased survival in telomerase-deficient mice with short telomeres, a result directly relevant to Maria Blasco's telomere biology research.
Rapamycin (sirolimus) is an FDA-approved immune-modulating and growth-inhibitory drug that allosterically inhibits mTORC1. It is widely discussed as a longevity intervention. In this study, the effect depended on the model: in wild-type mice, rapamycin extended lifespan, while in G2-Terc-/- mice (telomerase-deficient, with short telomeres) it decreased survival.
Maria Blasco is scientific director of the Spanish National Cancer Research Centre and leads its Telomeres and Telomerase Group. Her research focuses on how telomere biology shapes aging, cancer, and regenerative capacity. The rapamycin finding is directly relevant to her work: the two groups of mice differed in telomere state, and rapamycin extended lifespan in one while decreasing survival in the other. Whether telomere state caused the difference, or merely coincided with it, is not established from the available data. Blasco's specific role in the study is unknown.
The mechanism behind decreased survival in the telomerase-deficient mice is unknown, and so is the result's relevance to humans. The claim "rapamycin extends lifespan" holds for some mouse models, not all.
The edge captures a concrete, counterintuitive experimental finding: one compound produced opposite survival outcomes depending on telomere state, which makes it editorially sharp and useful for readers who encounter rapamycin as a straightforward longevity candidate. Blasco's research focus makes the connection substantive rather than incidental.